Subscribe To

Price Alert Latest News Economic Calendar News

MIST / Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 14.5% in 4 Weeks

The heavy selling pressure might have exhausted for Milestone Pharmaceuticals (MIST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. Read More

Demo Live Account See Partner Details

Content Topics

Here

Milestone

Pharmaceuticals

MIST

Poised

Turnaround

Here s

mist

Losing

Stock

Posted: Dec 13 2022, 11:17

Author Name: Zacks Investment Research

MIST News

By Seeking Alpha
May 22, 2023

Milestone Pharmaceuticals: Worthy Of A Dart Throw

Today, we take a deeper look at Milestone Pharmaceuticals Inc. for the first time on Seeking Alpha. The company's primary drug candidate has a novel d

By Zacks Investment Research
January 16, 2023

Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why

Milestone Pharmaceuticals (MIST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This

By Zacks Investment Research
December 13, 2022

Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 14.5% in 4 Weeks

The heavy selling pressure might have exhausted for Milestone Pharmaceuticals (MIST) as it is technically in oversold territory now. In addition to th

By Seeking Alpha
November 5, 2022

Milestone Pharmaceuticals: Potential NDA Submission Of Etripamil Catalyst Set For Mid-2023

Etripamil succeeded in phase 3 RAPID study, Milestone in talks with FDA to possibly file an NDA for this drug in treating PSVT patients by mid-2023. I

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.